Abstract 2092P
Background
Breast cancer tops the list of cancer types prevalent in Algeria, with more than 14,000 new cases recorded each year, of which a significant rate appears before the age of 40. it is aggressive and requires the use of chemotherapy known to be associated with immediate and long-term toxicities, which may affect the quality of life of cancer survivors. One of the chemotherapy-related long-term toxicities among premenopausal patients is hormonal changes with ovarian failure, chemotherapy-related amenorrhoea (CRA) and early menopause witch may lead to bone loss.The objectives were to evaluate bone mineral density (BMD) and to determine potential associated factors for bone loss among young premenopausal patients after adjuvant chemotherapy.
Methods
We included premenopausal Algerian aged <45 years who had received adjuvant chemotherapy. At study entry, background demographics, cancer characteristics and menstrual history were collected; BMD was measured by DXA in trabecular and cortical sites. Factors associated with reduced BMD and fracture risk were analyzed.
Results
A total of 83 patients were evaluated.The median age at the time of diagnosis of breast cancer is 37 years old, while the age at entry into the study is 43 years old. The median BMDs for femoral neck (FN) was 1.02 g/cm2 and lumbar spine (LS) 0.95 g/cm2; 37.2% had abnormal Z-scores (defined as ≤–1) and 44.7% had osteopenia/osteoporosis of either FN or LS. On multivariate analyses, factors that were identified correlated with bone loss (low BMD) are: young age at cancer diagnosis (OR [95% CI] = 2.103 [1.091–3.181), low Vitamine D level (OR = 2.254 [1.541–4.637]), low BMI (OR = 2.56 [1.599–2.907]), longer interval since last adjuvant treatment (OR for LS: 2.217 [1.250–4.357]), and having received adjuvant tamoxifen (OR = 1.752 [1.243–3.841]).
Conclusions
This study highlights that bone loss is prevelent condition in early breast cancer survivors who are on or after chemotherapy. About 44.7% of early breast cancer survivors found to have bone loss .To prevent bone fracture; certain factors associated with this condition deserve to be detected and corrected.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
HCA Hospital University of Algiers Algeria.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
2106P - Safety and patient reported outcomes of SARS-CoV-2 vaccination in patients with cancer
Presenter: Amy Body
Session: Poster session 06
2107P - Thromboprophylaxis with intermediate or prophylactic doses of LMWHs in ambulatory cancer patients
Presenter: Nikolaos Tsoukalas
Session: Poster session 06
2108P - Vitamin B12 and its clinical relevance in hospitalized cancer patients
Presenter: Stefano Maccarone
Session: Poster session 06
2109P - Vitamin A, D and E levels in patients with solid tumors undergoing palliative systemic cancer treatment
Presenter: Julia Berger
Session: Poster session 06
2111P - The value of multiple psychometric tools for distress screening and referral in a cancer population
Presenter: Daniel Anderson
Session: Poster session 06
2112P - Initial geriatric assessment and chemotherapy tolerability treatment in Brazilian patients with malignant neoplasm of the digestive system
Presenter: Marcos Dumont Bonfin Santos
Session: Poster session 06
2113P - Efficacy and effectiveness of prophylactic magnesium supplementation on prevention of cisplatin-induced nephrotoxicity: A systematic review and meta-analysis
Presenter: Caio Castro
Session: Poster session 06
2114P - Impact of comprehensive geriatric assessment (CGA) in the management of chemotherapy toxicity in older cancer patients
Presenter: Jordi Recuero-Borau
Session: Poster session 06
2115P - Pre-cachexia incidence in patients with solid cancer: A cross-sectional study
Presenter: Lynn Gottmann
Session: Poster session 06